Four Members of Congress Receive the 2001 Paul E. Tsongas Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WASHINGTON-Four members of Congress received the 2001 Paul E. Tsongas Memorial Award for their contributions to forwarding cancer research and awareness of the disease. This year’s honorees were Sen. Edward M. Kennedy (D-Mass), Sen. Mike DeWine (R-Ohio), Rep. C. W. Bill Young (R-Fla), and Rep. Lois Capps (D-Calif).

WASHINGTON—Four members of Congress received the 2001 Paul E. Tsongas Memorial Award for their contributions to forwarding cancer research and awareness of the disease. This year’s honorees were Sen. Edward M. Kennedy (D-Mass), Sen. Mike DeWine (R-Ohio), Rep. C. W. Bill Young (R-Fla), and Rep. Lois Capps (D-Calif).

The annual Tsongas award recognizes "outstanding legislative leadership and commitment in support of health care issues that result in improving the quality of life for all Americans."

It is presented by the Lymphoma Research Foundation of America and named for the late Sen. Paul Tsongas (D-Mass), who served as the group’s honorary chair from its inception until his death in 1997 from complications associated with his treatment for lymphoma.

The awards were presented at a Capitol Hill reception. Only Sen. Kennedy was able to attend the ceremony (see photograph). In his acceptance remarks, Sen. Kennedy noted that his son, Rep. Patrick J. Kennedy (D-RI), who was in the audience, received the Tsongas award last year.

"You see, he’s learning from me," Patrick Kennedy quipped to laughter and applause. "He’s coming along nicely."

In a more serious moment, Sen. Kennedy noted the successful work of the Human Genome Project and its potential. "When we look at the possibilities today, I firmly believe that this period of our time will be known as the time of the life sciences," he said. "It is the life sciences that are going to mark the way toward finding important paths for dealing with these challenges in lymphoma."

The senator, whose son Edward suffered from osteosarcoma as a child, also praised the efforts of advocacy groups like the Lymphoma Research Foundation. "I am all for what the government, the NIH, can do, and there is nothing that can replace that," Senator Kennedy said. "But the work this foundation does—in terms of the research it funds and in getting information out—is something that is enormously important, and I hope you know that."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.